Early FDA/Sponsor Meetings Expedite Novel Product Reviews In Some Cases
This article was originally published in The Gray Sheet
Executive Summary
Multiple review cycles for emerging technologies would be reduced, but not entirely eliminated, if industry and FDA were to meet earlier in the product development process, the agency finds